| Trial ID: | L2669 |
| Source ID: | NCT04324229
|
| Associated Drug: |
Liraglutide 6 Mg/Ml [Victoza]
|
| Title: |
Liraglutide in the Prevention of Type 2 Diabetes After Gestational Diabetes
|
| Acronym: |
Liragest
|
| Status: |
ACTIVE_NOT_RECRUITING
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Gestational Diabetes
|
| Interventions: |
DRUG: Liraglutide 6 MG/ML [Victoza]|DRUG: Placebos
|
| Outcome Measures: |
Primary: Incidence of type 2 diabetes, assessed by fasting P-glucose \>7 mmol/l and/ or 2 h \>11 mmol/l in oral glucose tolerance test (OGTT) 75g, and/or HbA1c≥ 6.5 %, from year 1 to 5 |
|
| Sponsor/Collaborators: |
Sponsor: Turku University Hospital
|
| Gender: |
FEMALE
|
| Age: |
CHILD, ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE (INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2020-02-07
|
| Completion Date: |
2027-12
|
| Results First Posted: |
|
| Last Update Posted: |
2023-12-06
|
| Locations: |
Turku University Hospital, Turku, 20521, Finland
|
| URL: |
https://clinicaltrials.gov/show/NCT04324229
|
